| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Etelcalcitide |
| Brand | Parsabiv® |
| Indication | For the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis. |
| Assessment Process | |
| Rapid review commissioned | 14/06/2017 |
| Rapid review completed | 01/09/2017 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price |
The HSE has approved reimbursement following confidential price negotiations; April 2018.